科源制药 (301281.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	448.3M	398.2M	463.7M	447.6M	442.9M
Cost of Revenue	199.7M	185.4M	258.4M	236.1M	261.6M
Gross Profit	248.7M	212.8M	205.3M	211.5M	181.3M
Operating Expenses
R&D Expense	38.2M	42.4M	35.8M	43.9M	27.0M
SG&A Expense	—	—	—	—	—
General & Admin Expense	54.8M	51.6M	39.7M	37.7M	28.2M
Selling & Marketing Expense	101.4M	80.6M	77.2M	63.4M	28.7M
Other Expenses	—	—	—	—	—
Total Operating Expenses	199.4M	178.4M	156.6M	145.0M	86.4M
Cost and Expenses	399.1M	363.8M	415.1M	381.1M	347.9M
Operating Income (EBIT)	45.7M	32.4M	68.3M	80.1M	98.2M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	25.8M	16.8M	65.7M	79.7M	98.3M
Income Tax Expense	2.0M	401.6K	5.4M	2.7M	7.0M
Bottom Line
Net Income	23.5M	16.6M	60.4M	77.0M	91.3M
Earnings from Cont. Ops	23.8M	16.4M	60.3M	77.0M	91.3M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	23.5M	16.6M	60.4M	77.0M	91.3M
Per Share
Basic EPS	CN¥0.22	CN¥0.15	CN¥0.56	CN¥0.76	CN¥1.12
Diluted EPS	CN¥0.22	CN¥0.15	CN¥0.56	CN¥0.76	CN¥1.12
Revenue Per Share	CN¥4.14	CN¥3.61	CN¥4.30	CN¥4.42	CN¥5.43
Shares
Basic Shares Outstanding	108.3M	110.4M	107.9M	101.4M	81.5M
Diluted Shares Outstanding	108.3M	110.4M	107.9M	101.4M	81.5M
Profitability Metrics
EBITDA	—	84.7M	115.5M	130.7M	133.5M
D&A	—	52.3M	47.2M	50.6M	35.3M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026